The introduction of oral antimicrobial agents with broadspectrum activity extending to methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and other multiply antibiotic-resistant pathogens made the fluoroquinolones an attractive choice for empirical therapy for an extensive range of conditions. As a consequence there has been heavy and indiscriminate use of these agents in some centres [1] [2] [3] [4] [5] [6] resulting in fluoroquinolone resistance emerging more rapidly than anticipated in certain pathogens, especially those that were only marginally susceptible. 3, 4, [7] [8] [9] With the recent releases of more potent agents such as trovafloxacin, grepafloxacin, sparfloxacin and levofloxacin, and others under development, there is now a concern that resistance to the newer agents may also develop. Two factors will be critical in determining the rate at which resistance to these agents develops-the manner in which fluoroquinolones (old and new) are used, and whether or not there are differences between the agents in their propensity to promote the development and spread of resistance.
Prescribing behaviours and infection control
The fluoroquinolones represented a new class of antimicrobial when they were introduced and there was, initially, a poorer understanding of their limitations compared with other more familiar classes of antibiotics. A high level of optimism arising from early publications, marketing launches and post-marketing activities probably contributed to fluoroquinolone overuse. Today, there is considerable experience with these agents and a better understanding of their optimal uses, benefits and limitations. For example, it is now understood that the factors responsible for the development of resistance to other antibiotic classes apply also to the fluoroquinolones. This now intuitively obvious fact is contrary to early speculations that the emergence of resistance to fluoroquinolones would be less common than occurred with other drug classes. 4 Therefore, as with other drug classes, attempts to minimize resistance must aim to restrict fluoroquinolone use to situations in which these agents are necessary, and to contain resistance that emerges by proven infection control procedures. 6 With this understanding firmly established, fluoroquinolones should now be used with greater wisdom than in the past. These considerations apply to all antibiotic classes, but there are also fluoroquinolone-specific considerations, in that some agents may retard the development of resistance more than others. Such agents can, therefore, be regarded as ecologically less harmful than others. This concept is discussed below. That is, if fluoroquinolone use can be restricted to appropriate indications, and ecologically preferable agents are used, it should be possible to reduce the selection pressure, and extend the effectiveness of the fluoroquinolone class of agents.
Ecologically preferred properties of fluoroquinolones
There are three main properties relevant to the ecological impact of a fluoroquinolone (in terms of its promoting or minimizing resistance): pharmacokinetics, potency and dissociated resistance.
pathogens at sites outside the urinary tract, e.g. norfloxacin, lomefloxacin and enoxacin. These agents are theoretically suboptimal because they are more likely to promote resistance in tissue infections and among the normal flora, especially the staphylococcal skin flora. Although there are no published human studies to validate this doctrine, it is supported by animal data showing that underdosing may cause resistance, 10 and by in vitro studies demonstrating that subinhibitory concentrations of fluoroquinolones are more likely to select less susceptible mutants than higher concentrations.
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Potency
There is general agreement that resistance is more likely to emerge in a single mutational step when an organism that is only marginally susceptible is exposed to a fluoroquinolone. 3, 4 This is because single-step mutations usually cause only modest decreases in susceptibility, i.e. eight-fold or less. [7] [8] [9] Agents that are highly potent are likely to prevent resistance emerging by killing both the parental organism and its less susceptible single-step mutant.
The importance of potency is demonstrated in Table I . Increased MICs of trovafloxacin, ciprofloxacin and ofloxacin resulted when first-step mutants were selected from a clinical isolate of Streptococcus pneumoniae after exposure to trovafloxacin and ciprofloxacin. The MIC increases were typically eight-fold or less. However, because trovafloxacin was up to 32-fold more potent than ciprofloxacin and ofloxacin against the mutants, the mutants remained susceptible only to trovafloxacin. Extrapolating these results to the clinical situation, trovafloxacin was the only agent in this study that was likely to prevent resistance emerging by being able to kill both the parent and its mutants.
Dissociated fluoroquinolone resistance
Dissociated fluoroquinolone resistance is the phenomenon whereby a resistance mechanism significantly reduces the activity of one agent more than another. A dramatic example of this was a multi-step mutational study in which fluoroquinolone MICs of the third-step mutant of S. aureus obtained after exposure to ofloxacin exhibited a 256-fold increase in the MIC of grepafloxacin but only eight-fold increases in the MICs of ciprofloxacin and ofloxacin. 12 That is, grepafloxacin was 32-fold more affected than ciprofloxacin and ofloxacin by this mutational step. At present there is only partial understanding of the mechanisms responsible for this type of phenomenon. However, it is clear that fluoroquinolones are not all equally affected by resistance mechanisms.
The underlying basis for dissociated resistance is beginning to be clarified by molecular studies. For example, it has been shown that certain mutations are phenotypically silent against some fluoroquinolones but can cause modest increases in the MICs of others, and multiple mutations appear to be necessary to cause the dramatic differentials between fluoroquinolones of the type mentioned above. Fournier and Hooper, 13 showed that the occurrence of single specific mutations in the genes of DNA gyrase subunits A and B (gyrA and gyrB) of a strain of S. aureus did not alter the MICs of ciprofloxacin, norfloxacin or sparfloxacin, while a mutation in the topoisomerase IV gene (grlA) increased the MICs of ciprofloxacin and norfloxacin four-and 16-fold, respectively, without altering the MIC of sparfloxacin. Furthermore, when the previously silent gyrA and gyrB mutations were combined with the grlA mutation, the sparfloxacin MIC increased 128-fold, but the MICs of ciprofloxacin and norfloxacin increased only 16-and four-fold, respectively. Studies have also identifed molecular events that are associated with dissociated fluoroquinolone resistance in S. pneumoniae. 14, 15 More studies are required for a comprehensive and clinically useful understanding of the effects of the variety of mutations and combinations of mutations that occur in clinical isolates. It is currently known that mutations in the quinolone resistance-determining regions of the chromosome can affect different fluoroquinolones idiosyncratically, causing phenotypic unpredictability. 13, 16 However, until more complete data are available, it is too early to expect molecular analyses to predict reliably all possible resistance phenotypes. The unpredictability and complexity of the clinical situation is reflected in the three clinical isolates of S. aureus shown in Table II . Strain 202 is more resistant to ciprofloxacin than to grepafloxacin. In contrast, strain 205 is more resistant to grepafloxacin than ciprofloxacin, while strain 204 has similar MICs of both drugs. All strains are highly resistant (ciprofloxacin MICs у 8 mg/L), suggesting that multiple mutations are present and therefore that different combinations of mutations are responsible for the different phenotypes. The considerable variability of these isolates suggests that caution is necessary when applying the results of molecular studies of single strains with only a few specific mutations to the more diverse clinical situation.
A more useful approach to dealing with the potential diversity of resistance mechanisms in clinical isolates is suggested by the Figure. This figure shows the in vitro potencies of ciprofloxacin and sitafloxacin against a collection of 54 isolates of S. aureus from patients throughout the USA, Europe and Australia. 17 The isolates were chosen because they possessed differing levels of fluoroquinolone resistance and were obtained from diverse sources, thereby providing a broad representation of strains and resistance mechanisms. By comparing the lines representing the cumulative percentages of strains inhibited at each drug concentration, it is evident that the distance between the ciprofloxacin and sitafloxacin lines was greater in tests with the highly resistant strains, than in tests with the highly susceptible strains. This reflected changes in relative potency as resistance increased. Against the highly ciprofloxacinsusceptible isolates (MIC р 0.25 mg/L), sitafloxacin was eight-fold more potent than ciprofloxacin, whereas against the highly resistant strains (ciprofloxacin MIC у 8 mg/L) sitafloxacin was 64-to 128-fold more potent. Therefore, the potency of sitafloxacin increased eight-to 16-fold relative to ciprofloxacin as fluoroquinolone resistance increased. Sitafloxacin was less affected overall by the resistance mechanisms of the strains irrespective of the types of mechanisms present. It was, therefore, both the more potent agent and the last affected overall by dissociated resistance, making it ecologically preferable to ciprofloxacin.
This type of analysis yields potentially useful information about the activities of different fluoroquinolones against bacterial populations in which there are less susceptible strains. A compilation of the results of several studies of this nature is provided in Table III . Since the results are from studies that focused mainly on the anti-staphylococcal activities of the fluoroquinolones, there are fewer drugs compared against the Enterobacteriaceae and nonfermenter groups of organisms. In general the trends appear to be applicable to both Gram-positive and -negative organisms. For example, against all three organism groups, ciprofloxacin and CI-990 were more affected by the fluoroquinolone resistance mechanisms than ofloxacin, clinafloxacin and sparfloxacin. Trovafloxacin, moxifloxacin, gatifloxacin, temafloxacin, sitafloxacin and levofloxacin were also less affected than ciprofloxacin or CI-990 by the mechanisms responsible for increasing fluoroquinolone resistance in staphylococci, but were not evaluated in this manner against the Gram-negative organisms. Clinafloxacin and sitafloxacin were less affected than any of the other fluoroquinolones by the staphylococcal resistance mechanisms, with both agents increasing eight-to 16-fold in potency relative to ciprofloxacin and CI-990 as resistance increased. Grepafloxacin was unique in its anti-staphylococcal activity, being the only agent that showed inconsistent results. It was less affected than ciprofloxacin by the resistance mechanisms of most clinical isolates, but against a subset of isolates it was more affected than ciprofloxacin. The clinical isolates of the subset were phenotypically similar to laboratory mutants previously described, 12 in which the resistance mechanisms of the third-step mutants greatly reduced the activity of grepafloxacin.
At present there are no large collections of clinical isolates of S. pneumoniae with varying levels of fluoroquinolone resistance available for studies of this nature. Comparative potencies of sitafloxacin (᭺, highly susceptible strains; ᭹, highly resistant strains) and ciprofloxacin (᭛, highly susceptible strains; ᮀ, highly resistant strains) against Staphylococcus aureus isolates with different levels of resistance to ciprofloxacin. Ciprofloxacin MICs for 18 highly susceptible strains were р0.25 mg/L, and for 19 highly resistant strains were у8 mg/L. Adapted from reference 17. However, mutational studies with this organism suggest that ciprofloxacin is more affected than ofloxacin, levofloxacin, sparfloxacin, clinafloxacin, gatifloxacin, grepafloxacin, moxifloxacin and trovafloxacin by first-step mutations. 14, 18 These mutational studies add support to the concept that dissociated resistance trends may be widely applicable to many types of bacterial pathogens.
It can be argued that dissociated resistance is clinically irrelevant and only of academic interest if it occurs only at drug concentrations higher than those achieved in humans. The merit of this criticism is difficult to assess. Different fluoroquinolones can have very different intrinsic potencies against different organisms (e.g. S. aureus in comparison with S. pneumoniae or Escherichia coli), making dissociated resistance clinically relevant in the more susceptible genera, even if it is not in those that are less susceptible. Furthermore, an organism that is 'highly resistant' to one fluoroquinolone may still be susceptible to another more potent agent (e.g. clinical isolates of S. aureus with a trovafloxacin MIC of 1 mg/L and a ciprofloxacin MIC of 128 mg/L). Ultimately, for some isolates, MICs of all fluoroquinolones may be elevated sufficiently to exceed clinically attainable concentrations, but for other less resistant isolates of the same species the dissociated resistance characteristics may be therapeutically and ecologically relevant. In addition, the consistent patterns of dissociated resistance reported in Table III are suggestive of general principles that may be applicable to many, possibly all, organism groups. Although this may not have direct therapeutic implications for the individual patient, there may be advantages in having a better understanding of the drugorganism interactions of the various fluoroquinolones when considering their potential clinical roles. In this context, dissociated resistance analyses may be more helpful to identify agents that are ecologically desirable than the more traditional MIC studies of the past in which mostly susceptible wild-type isolates were tested, and which may be misleading about the long-term utility of the agents.
Conclusion
Given the concerns about the newer fluoroquinolones promoting the development and spread of resistance, there appear to be grounds for cautious optimism. Wisdom gained from previous use of the older fluoroquinolones should have convinced clinicians of the need to reserve these agents for situations in which they are drugs of choice. Furthermore it is possible to identify agents that are likely to be ecologically preferable because they have a lower propensity to promote resistance. These are agents that have favourable pharmacokinetic properties, enhanced potency and good dissociated resistance characteristics.
